加载中
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
收盘时
US$1.85
+US$0.015 · +0.82%
盘后
US$1.86
+US$0.01 · +0.54%
10月13日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
日内区间
当前US$1.85
52周区间
当前US$1.85
盘中时间采用ET。市场数据可能有所延迟。
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
日内区间
当前US$1.85
52周区间
当前US$1.85
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 445.3万 USD | 531.1万 USD | 541.5万 USD | 533.9万 USD | 1887.14万 USD |
| 销货成本 | 409.1万 USD | 481.3万 USD | 480.4万 USD | 489.3万 USD | 1589.4万 USD |
| 毛利 | 36.2万 USD | 49.8万 USD | 61.1万 USD | 44.6万 USD | 297.74万 USD |
| 研究与开发 | 78.8万 USD | 102.3万 USD | 149.1万 USD | 158.4万 USD | 181.24万 USD |
| 销售、一般及管理费用 | 489.4万 USD | 461.2万 USD | 548.7万 USD | 608.5万 USD | 569.9万 USD |
| 营业费用 | 568.2万 USD | 563.5万 USD | 697.8万 USD | 766.9万 USD | 751.14万 USD |
| 利息收入 | 123.3万 USD | 16.5万 USD | 43.1万 USD | 13.3万 USD | 2.7万 USD |
| 折旧和摊销 | 42.1万 USD | 40万 USD | 37.4万 USD | 35.1万 USD | 59.48万 USD |
| 营业利润 | −532万 USD | −513.7万 USD | −636.7万 USD | −722.3万 USD | −453.4万 USD |
| 净利润 | −377.5万 USD | −497.3万 USD | −597.8万 USD | −714万 USD | −453.1万 USD |
公司数据更新于 2026年10月14日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅3项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年4月21日 | 1:8 | — | — |
股票拆分 | 1994年11月14日 | 1:2 | — | — |
股票拆分 | 1980年12月15日 | 3:2 | — | — |
股票拆分 | 1980年6月30日 | 5:4 | — | — |
已生效 2025年4月21日
1:8
已生效 1994年11月14日
1:2
已生效 1980年12月15日
3:2
已生效 1980年6月30日
5:4
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
